URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$17.20 (+101.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
UroGen Pharma Ltd. grew revenue 100.3% to $188.73M over the twelve months to Jun 30, 2026. Free cash flow was -$159.14M.
Revenue
$188.73M
+100.3% vs. a year earlier
Operating income
-$66.65M
TTM Q2 2026
Free cash flow
-$159.14M
TTM Q2 2026
EPS, diluted
-$1.98
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.72B
- P/E ratio
- –
- Price to sales
- 9.12
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -9.25%
Fundamentals
- Revenue
- $188.73M
- Net income
- -$97.64M
- EPS, diluted
- -$1.98
- Free cash flow
- -$159.14M
- Book value per share
- -$2.63
- Diluted shares
- 50M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$188.73M+100.3% YoY
Gross profit
$171.46M+105.5% YoY
Operating income
-$66.65M
Net income
-$97.64M
EPS, diluted
-$1.98
Free cash flow
-$159.14M
Reported periodTrailing twelve months